Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Diane Opatt

Showing results (1-10 of 5) with videos related to

Pageof 1
Sort By:
Annals of Surgical Oncology|May 19, 2007
Conflicts in decision-making for breast cancer surgeryDiane Opatt, Monica Morrow, Sarah Hawley, et al.
Breast Cancer Research and Treatment|October 30, 2013
Phase II randomized trial of weekly and every-3-week ixabepilone in metastatic breast cancer patientsJohn W Smith, Svetislava Vukelja, Amy Rabe, et al.
Clinical Breast Cancer|June 5, 2012
Maintenance of clinical efficacy after dose reduction of ixabepilone plus capecitabine in patients with anthracycline- and taxane-resistant metastatic breast cancer: a retrospective analysis of pooled data from 2 phase III randomized clinical trialsVicente Valero, Eduard Vrdoljak, Binghe Xu, et al.
The Lancet. Oncology|October 5, 2015
Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trialJean Jacques Grob, Mayur M Amonkar, Boguslawa Karaszewska, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 27, 2016
Overall Survival and Durable Responses in Patients With BRAF V600-Mutant Metastatic Melanoma Receiving Dabrafenib Combined With TrametinibGeorgina V Long, Jeffrey S Weber, Jeffrey R Infante, et al.
Pageof 1

Showing results (1-10 of 5) with videos related to

Sort By:
Pageof 1
Annals of Surgical Oncology|May 19, 2007
Conflicts in decision-making for breast cancer surgeryDiane Opatt, Monica Morrow, Sarah Hawley, et al.
Breast Cancer Research and Treatment|October 30, 2013
Phase II randomized trial of weekly and every-3-week ixabepilone in metastatic breast cancer patientsJohn W Smith, Svetislava Vukelja, Amy Rabe, et al.
Clinical Breast Cancer|June 5, 2012
Maintenance of clinical efficacy after dose reduction of ixabepilone plus capecitabine in patients with anthracycline- and taxane-resistant metastatic breast cancer: a retrospective analysis of pooled data from 2 phase III randomized clinical trialsVicente Valero, Eduard Vrdoljak, Binghe Xu, et al.
The Lancet. Oncology|October 5, 2015
Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trialJean Jacques Grob, Mayur M Amonkar, Boguslawa Karaszewska, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 27, 2016
Overall Survival and Durable Responses in Patients With BRAF V600-Mutant Metastatic Melanoma Receiving Dabrafenib Combined With TrametinibGeorgina V Long, Jeffrey S Weber, Jeffrey R Infante, et al.
Pageof 1